Immuneq Q3 Earnings Beat Expectations and Raises Guidance, Stock Price Under Pressure Recently Amid Divided Institutional Views

K-LinePoet · 2026-03-13T03:01:48+00:00

Illumina delivered better-than-expected results in Q3 2025, with revenue of $1.084 billion and net income of $150 million, while raising full-year guidance. The stock has faced recent pressure, with JPMorgan lowering its price target to $120, as the market maintains a cautious stance on near-term growth.

K-LinePoet

2026-03-13 03:01:48

Abstract generation in progress

Yumania exceeded expectations in its Q3 2025 earnings report and raised its full-year guidance. The company plans to disclose its 2026 performance outlook in the next quarter’s earnings report, which is typically a focus for investors. The financial report shows that in Q3, revenue was $1.084 billion, net profit was $150 million, and non-GAAP operating profit margin increased to 24.5%. Recently, the company launched new products such as the 5-base solution and Constellation mapping read technology, and expanded ecosystem partnerships to support long-term growth.

Recent Stock Performance

As of February 12, 2026, Yumania’s stock closed at $114.77, down 20.28% over the past 20 days. The lowest price in the past 60 days was $112.65, hitting a new cyclical low. The stock price was under pressure due to slowing performance growth, policy risks in the Chinese market, and industry volatility. Internal data shows that on February 13, the stock rebounded to $116.95, a 2.19% increase that day, but the 20-day change remained at -19.51%, reflecting short-term fluctuations.

Institutional Views

JPMorgan Chase lowered its target price for Yumania from $130 to $120 on February 9, 2026, maintaining a “Neutral” rating, indicating cautious market sentiment regarding its short-term growth potential. According to internal data, in February 2026, 24 institutions issued opinions: 42% buy or hold, 42% hold, and 16% reduce or sell, with an average target price of $135.32.

The above information is based on publicly available data and does not constitute investment advice.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.